The procedure involved an investigational endovascular device, the Gore Excluder Thoracoabdominal Branch Endoprosthesis, which was placed into the patient’s aorta. The device works by preventing a rupture and maintaining blood flow to organs.
The patient received three small incisions and was hospitalized for six days. Both incision size and hospital stay typically required after traditional open heart surgery were reduced.
Clinical trials are being conducted at OSU and other hospitals in the region. Gore & Associates, the device manufacturer, is awaiting approval from the FDA for the device to become the first one to be made commercially available.
More articles on cardiology:
American Heart Association updates CPR guidelines: 5 key changes
Yale launches study on digital health tech for cardiac patients
MRIs safe for patients with implanted heart devices, study finds
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.